Group items tagged

The National Pharmacy Association (NPA) has announced that the Chief Pharmaceutical Officer for England, David Webb will be among the keynote speakers at the Pharmacy Odyssey Conference on 13 October. He and other special guests will discuss the future of community pharmacy within the NHS, during a day of insight and practical advice for pharmacy teams. The NPA promises expert opinion on the current pressures in the sector and a thorough exploration of the long-term picture. NPA Director of Membership, Simon Tebbutt, explains: "With the NPA centenary in 2021 behind us, this will be a foray into the future - mapping the coming decade, and next half-century - as well as covering the many challenges of the present time." The theme of the conference, to be held online and sponsored by Novo Nordisk, is Pharmacy Odyssey: Services, Supply and Sustainability.

The Royal Pharmaceutical Society (RPS)'s new research (YouGov poll) revealed that one in five of UK adults (19%) keep their medicines in the bathroom. The research revealed, "Almost one in two (45%) of UK adult keep their medicines in the kitchen, which could also cause problems. RPS Chief Scientist Professor Parastou Donyai said: "It's important to store your medicines in the right place as this could affect how they work. "Medicines should be stored in a cool, dry place and are particularly affected by heat and moisture. Keeping your medicines in the same place as where you have baths and showers could make your medicines less effective or spoil them. "Instead keep your medicines in another room, for example your bedroom or if you keep them in the kitchen, make sure this is in a kitchen cabinet, away from sources of heat such as the hob, oven or windowsill. If you have small children or pets in the home, always make sure your medicines are kept in a lockable storage box somewhere out of their reach and sight."

Community pharmacies are located within the very hotspots of peoples' communities, yet a staggering 720 individual businesses have stopped trading since 2015. It has been called a "national disgrace and a betrayal to the elderly and the vulnerable" by sector leaders. The funding crisis has been compounded by a gruelling 18-24 months post-Covid, both have which have placed immense pressure on the retail pharmacy sector. The population is aging and with this comes patients living with a range of long-term health conditions. Medication regimes are becoming ever more complex and as a result, maintaining prescription and medication adherence services is challenging to say the least. Yet the public feel great warmth towards their local pharmacy businesses, and this positive attitude only increased during the pandemic. In fact, in a recent report launched by Omnicell on the Changing Role of the Pharmacist, a survey of public opinion found that a third (32 per cent) said they perception of their local pharmacy had changed for the better since the start of the pandemic and nearly half (44 per cent) said they are more familiar with their local pharmacy services since the start of COVID. This has meant that the role of the pharmacist has also changed and evolved; in part due to a national need and drive for more patients to be seen and supported clinically by pharmacists. This change of service provider role has slowly been developing over the last couple of years. Pharmacists are currently carrying out 65 million consultations a year - a staggering rise of 44 per cent in the last 24 months alone.

An alliance of companies has pledged to ensure equitable access to vaccines and treatments for pandemics, as the friction around intellectual property rights for Covid-19 interventions between the pharmaceutical industry and developing nations endures. At the heart of the plan is a commitment to set aside part of the production of vaccines and treatments upfront for vulnerable populations in low-income countries when the next pandemic arises, given how fragmented access to Covid tools has left many populations unprotected. In order to do better next time - and without knowing which companies will develop the first drugs and vaccines for the next pandemic - having the industry collectively make this commitment is potentially transformative, said Thomas Cueni, head of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). The pledge, called the Berlin Declaration, was made on July 19 by members of the global pharmaceutical industry group that include many of the companies involved in developing Covid interventions, such as AstraZeneca, GSK, Moderna, Pfizer and Merck. The declaration is not legally binding. However, if a company that signed on reneges on its vow, it would face grave consequences in the court of public opinion, said Cueni.

Former chancellor Rishi Sunak, one of two candidates vying to be Britain's next premier, criticised the way outgoing prime minister Boris Johnson handled the Covid-19 pandemic, saying it had been a mistake to "empower" scientists and that the downsides of lockdowns were suppressed. The Tories are choosing a new leader after Johnson was forced to quit when dozens of ministers resigned in protest at a series of scandals and missteps. Party members are voting to select either Sunak or foreign secretary Liz Truss, who will take over next month. Opinion polls show Sunak is behind in race. The handling of the pandemic has become an issue, with Truss saying this month she would never again approve another lockdown and also asserting that as trade minister at the time she was not involved in taking the key decisions about how to respond. Sunak said the government had been "wrong to scare people" about coronavirus. He said he was banned by officials in Johnson's office from discussing the "trade-offs" of imposing coronavirus-related restrictions, such as the impact on missed doctor's appointments and lengthening waiting lists for healthcare in the NHS.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approving an oral therapy to treat myelofibrosis patients with moderate to severe anaemia. Myelofibrosis is a rare blood cancer that affects the body's normal production of blood cells, and the affected patients are likely to develop anaemia over the course of the disease. British drugmaker GSK, the manufacturer of the oral therapy known as momelotinib, said that it can be used to treat "both newly diagnosed and previously treated myelofibrosis patients." The medicine helps address disease-related splenomegaly (enlarged spleen) or symptoms in adult patients who are Janus kinase (JAK) inhibitor naïve or have been treated with ruxolitinib, as stated by the company. Nina Mojas, Senior Vice President of Oncology Global Product Strategy at GSK, said that receiving the positive CHMP opinion "is a significant step in bringing momelotinib to patients in the EU with this difficult-to-treat blood cancer."

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned the public to avoid buying pre-filled weight loss pens without a prescription. The warning came after 369 fake Ozempic injections have been seized since January 2023. However, Saxenda pens were obtained by members of the public in the UK through "non-legitimate routes". The health regulator has urged the public to buy the pens after consulting a healthcare professional and with a prescription. Dr Alison Cave, MHRA Chief Safety Officer shared her opinion on the matter, she said: "Buying products such as Ozempic or Saxenda without a prescription, from illegally trading suppliers, significantly increases the risk of receiving something which is either fake or not licensed for use in the UK.

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on plans to reclassify a locally-applied hormone replacement therapy product to treat the cause and relieve the symptoms of vaginal atrophy. The MHRA is proposing that Gina 10 microgram vaginal tablets, containing oestradiol, be made available over the counter as a "self care" product, under the supervision of a pharmacist. The Commission on Human Medicines too has advised that the application by Novo Nordisk, which is used to treat vaginal dryness, caused by oestrogen deficiency in postmenopausal women, can be made available as a pharmacy (P) medicine. The MHRA has been asking GPs, pharmacists and members of the public for their opinions on whether the tablets can be made available to women aged 50 and over who have not had a period for at least a year. If the reclassification goes ahead, pharmacists will be given training materials and a checklist to help them supply the medicine safely.

The Royal Pharmaceutical Society has opened a survey which asks its members how they would want to take part in and learn about decisions made by the RPS. The RPS said the survey was a core part of the independent review of member participation and communications led by communications consultancy Luther Pendragon. It said: "We will be asking our members to join focus groups to give their opinions on how participation can be developed and strengthened, and how RPS communications about decisions it has taken on behalf of the profession through its governance boards can be improved. We will also be asking our elected members and key external stakeholders for their views over the coming weeks." The Luther team will then build a series of recommendations for RPS and develop a corporate communications strategy which will include action plans to enable greater participation. RPS president Claire Anderson said: "We want to hear from as many of you as possible through our survey to inform how the organisation works with and engages with you, our members.

The One Show on BBC One has put community pharmacy in the limelight, showcasing the sector's vital work during the pandemic to a primetime TV audience. The five minute segment, aired on May 10, featured Sutton pharmacist Reena Barai and a reception at St. James's Palace for around 200 pharmacists, including Barai, hosted by the Prince of Wales on May 4. "It was great to be part of such a positive story," Barai, who is a board member of the National Pharmacy Association (NPA), said. "It's heartening that the national media are taking notice of the sector, because it's too often overlooked. Coverage like this both reflects public opinion and shapes it, that's why the NPA works so hard on keeping us in the public eye." The segment told the story of community pharmacy's role during the pandemic and contained footage of a speech by the Prince of Wales, praising the sector for its contribution to the nation's healthcare. "Pharmacists are about people and places, not just pills, a place where science, as it were, meets society. I just want to thank you all, more than I can possibly say, for everything you do so brilliantly to keep people well, and above all, save lives. Thank you, everybody," Prince Charles is seen saying at the reception.

The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition. NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.

Representatives from the national community pharmacy bodies will brief the MPs on the severe challenges facing community pharmacies on Tuesday (21 March) at a roundtable summit. The roundtable summit will include discussions on the urgent action needed to address the current severe challenges being faced by community pharmacy, as well as the sector's role in the upcoming Primary Care Recovery Plan, said PSNC. The Parliamentary event this week has been coordinated by PSNC as part of the joint #SaveOurPharmacies campaign which exceeded 30,000 signatories in a week. The Association of Independent Pharmacies (AIM), the Company Chemists' Association (CCA), the National Pharmacy Association (NPA) and PSNC will take part at the event. A spokesperson for the #SaveOurPharmacies campaign group said: "30,000 signatures in a week indicates a high level of underlying public support for community pharmacy and it's a good start to the #SaveOurPharmacies campaign. A petition by itself won't change the world, but it works as a kind of drumbeat for the campaign, giving forward momentum, and it's a really easy way to express your opinion. We hope the new window poster - along with all the resources available at saveourpharmacies.co.uk - will help as many pharmacies as possible to drum up support from their patients, and we're really grateful to Communications International Group for helping us to print and distribute this.

The Pharmacist's Defence Association (PDA) has raised concerns over the adoption of Digital Clinical Excellence (DiCE) guidelines for online prescribing of GLP-1 receptor agonists for weight management in adults. This follows a clash with expert recommendations commissioned by the General Pharmaceutical Council (GPhC) as the PDA "believes the final guidance conflicts with the expert opinion underpins the GPhC's prosecution strategy towards pharmacist prescribers under investigation." In a recent statement, the PDA highlighted the discrepancy between DiCE's guidance and the expert report employed by the GPhC to prosecute pharmacist prescribers using a questionnaire-based consultation model. This conflict has prompted the PDA to withhold its endorsement of the DiCE guidance as it differs from an expert report commissioned by the GPhC. The PDA's reservations stem from the inherent risks associated with questionnaire-based prescribing.

Many of us know that oral health plays a hugely important role in our general health and wellbeing. We're continuing to see a rise of cosmetic dentistry such as veneers and teeth whitening[1] but fundamentally, it shouldn't be forgotten that oral health encompasses so much more than aesthetics. Our diets, the oral hygiene products we are using, and our brushing techniques are all elements that impact our oral health. It's been hard to miss in the news that there is a dental crisis in the UK, with 'dental deserts' leaving some areas with over 3,000 patients for every NHS dentist[2]. With oral health being of such importance to our overall health[3], it's only reiterated to us at Haleon that we must continue to promote access to dental care and understanding of better dental health. As I've mentioned in previous articles for Pharmacy Business, an understanding of preventative, self-care is hugely beneficial, not just to improve health inclusivity but to help reduce these current burdens on both healthcare and dentistry professionals. We know that at Haleon, we, and the consumer healthcare industry as a whole, have a responsibility to empower people to equip themselves with the tools and information to participate in their own and loved ones' health - and dental health is such an important part of that.

Diabetes affects over 537 million people worldwide; by 2045, this is estimated to increase to 783 million. [1] With the growing prevalence of diabetes, it's even more important to utilise all options to support people with diabetes (PwDs) in managing their daily life with diabetes. Where do PwDs most often access healthcare support? On average, PwDs visit the pharmacy three-to-eight times more than the general population to obtain medicines and testing supplies.[2] It is clear that pharmacists play an integral role in empowering the self-management needs of PwDs beyond the traditional role of supplying medicines. This relationship, however, may be underutilised. Research suggests there is a lack of broad recognition of pharmacists as a key source of diabetes care, and that resource constraints - particularly following the COVID-19 pandemic - can interfere with patient education provision and training.[3,4] Furthermore, the circumstances and role of the pharmacy vary, nationally and internationally. At Roche Diabetes Care we would like to shine a light on the increasing value of community pharmacists as important figures in the well-being of PwDs.

It's no secret that as pharmacists we are navigating a new and more demanding healthcare landscape. Our role has changed significantly since the start of the 21st century due to increased expectations from the public, advances in science and technology and changing workforce pressures. The Community Pharmacy Contractual Framework for England has placed a higher focus on clinical service. In addition, the Covid-19 pandemic resulted in significant acceleration in changing how we work day-to-day and the public perception of our role. Community pharmacy owners and staff have been under relentless pressure for the last two years. Dispensing volumes are continually increasing but dispensing revenues are being replaced by launching new services. We must find solutions to reduce the time it takes to dispense medication so we can focus on these new revenue generating services. To not just succeed, but to thrive, it is becoming increasingly important to understand and embrace the technology available.

Online pharmacies have to operate from bricks & mortar premises that are registered with the General Pharmaceutical Council, but recent cases show that, in reality, the practices of online pharmacies are often very different to other pharmacies, and the regulation of online pharmacies is also different - and evolving as issues arise. For a start, the General Pharmaceutical Council (GPhC) is only one of the regulators taking an interest in online pharmacy services. Other regulators include the Medicines and Healthcare products Regulatory Agency (MHRA) which enforces the advertising and promotion of medicines, and the Care Quality Commission (CQC) which regulates prescribing services. The different regulation of online pharmacies is attributable to the higher risk to patients and the public from medicines bought online. These risks often arise from a combination of patients who do not tell the truth in order to obtain medicines and the nature of a transaction in which a pharmacist does not see patients face-to-face. "The GPhC has strong enforcement powers that it uses when it considers its premises standards have not complied with." However, there are also things that go wrong because pharmacists have simply failed to act professionally or take sufficient care, as well as cases where things have gone wrong through misfortune.

This is where we often search for safe, natural solutions; "Glucofix" will provide you exceptional immunity and a regulated bodily system. Its amazing response can be attributed to the herbal extracts that it contains.